Journal of Cardiac Failure最新文献

{"title":"Tricuspid Edge-to-Edge Repair in Patients With Prior Cardiac Transplantation: Results From the TRILUMINATE Pivotal Trial.","authors":"Brian Whisenant, Rami Alharethi, Samir Kapadia, Anson Jay Conrad Smith, Stephen Little, Ulrich Jorde, Raymond Benza, Andrew Sauer, Sandhya Murthy, Nadira Hamid, Jacob Zbinden, Kelli Peterman, Paul Sorajja, David Adams","doi":"10.1016/j.cardfail.2026.09.027","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.027","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Values-Centered Discussions Among Family Caregivers of Patients with Left Ventricular Assist Devices: A Mixed Methods Study.","authors":"Ashmita Thapa, Martha Abshire Saylor, Mireille Chehade, William Waldron, Adam Tyson, Donne Donald, Lucinda Graven, Geunyeong Cha, Debra K Moser, Colleen K McIlvennan, Avery C Bechthold","doi":"10.1016/j.cardfail.2026.09.028","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.028","url":null,"abstract":"<p><strong>Background: </strong>Family caregivers of left ventricular assist device (LVAD) recipients play a central role in managing complex care and navigating ongoing healthcare decisions. Although personal values may influence caregiving experiences and decision-making, little is known about how caregivers engage in values-centered discussions with the healthcare team.</p><p><strong>Objective: </strong>To examine LVAD caregivers' engagement in values-centered discussions and identify factors influencing these interactions.</p><p><strong>Methods: </strong>A sequential explanatory mixed methods study among LVAD caregivers at an outpatient mechanical circulatory support clinic in the Southeastern United States. Survey data were analyzed using descriptive statistics to summarize patterns of values-centered discussions. Interviews with a subset of participants were analyzed using thematic analysis to identify factors influencing these interactions. Quantitative and qualitative findings were integrated using joint displays.</p><p><strong>Results: </strong>Caregivers (N=32) reported high levels of feeling heard and understood in healthcare interactions (median [IQR], 3.50 [3.00-4.00] and moderate assertiveness in communicating care-related concerns (median [IQR], 7.00 [4.00-8.00]). Values discussions most often occurred with spouses/partners (75%), family members (69%), and LVAD coordinators (56%). Discussions were more common after implantation (89%) and during hospitalizations (93%) and clinic visits (86%) than via telehealth (31%). Three themes (n=11) explained these patterns: emotional readiness, relational trust, and situational context. Emotional overwhelm in the early post-implant period limited discussions, whereas trust, accessibility, and longitudinal relationships facilitated engagement.</p><p><strong>Conclusions: </strong>Values-centered discussions depend not only on opportunity but also emotional readiness, healthcare team relationships, and care context. Prioritizing relationship-building and ongoing opportunities for discussion may enhance engagement and support more value-concordant advanced heart failure care.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacubitril/Valsartan Versus ACEi/ARB Across the Ejection Fraction Spectrum: A Multistate Real-World Cohort.","authors":"Michel Chedid El Helou, Karim Hoyek, Harsh Patolia, Michael Hill, Ziad Zalaquett, Hunter Block-Beach, Ashish Sarraju, Amanda R Vest, Nancy M Albert, Randall C Starling, Trejeeve Martyn","doi":"10.1016/j.cardfail.2026.09.021","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.021","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Mineralocorticoid Receptor Antagonist Initiation in Newly Diagnosed Heart Failure.","authors":"Gregg C Fonarow, Carolyn S P Lam, Alanna A Morris, Yik Ming Fung, Zihe Zheng, Sonia Gomez, Katsiaryna Holl, Marco Antonio Lavagnino, Arvind Katta, Rachel Knapp","doi":"10.1016/j.cardfail.2026.09.025","DOIUrl":"10.1016/j.cardfail.2026.09.025","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Hospital Initiation of SGLT2 Inhibitors: Why We Should Stop Waiting.","authors":"Ottavio Zucchetti, Michele Senni","doi":"10.1016/j.cardfail.2026.09.032","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.032","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Comorbidity-Driven Interleukin-6-Mediated Systemic Inflammation Hypothesis of Heart Failure With Preserved Ejection Fraction: A Decade of Testing Ends in Disappointment.","authors":"Milton Packer, Javed Butler, Faiez Zannad, Muthiah Vaduganathan, Barry A Borlaug","doi":"10.1016/j.cardfail.2026.09.029","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.09.029","url":null,"abstract":"<p><p>In 2013, Paulus and Tschöpe proposed that the multitude of comorbidities seen in patients with heart failure with preserved ejection fraction (HFpEF) was causally responsible for triggering an interleukin-6 (IL-6)-mediated systemic inflammatory state that might lead to HFpEF, postulating the intermediary contribution of coronary microvascular disease and deficient nitric oxide/cyclic guanosine monophosphate (NO-cGMP) signaling and cytokine-mediated cardiac hypertrophy and fibrosis. The comorbidity-driven IL-6-systemic inflammation hypothesis has been extensively evaluated in randomized controlled trials. However, in these trials, most comorbidities have not been shown to represent a causal mechanism for systemic inflammation, and the treatment of comorbidities (other than obesity) has not ameliorated HFpEF. Although coronary microvascular dysfunction is common in HFpEF, it is often not endothelium-dependent, and it is not a cause of defective NO-cGMP signaling. Numerous randomized clinical trials with NO-cGMP enhancing drugs (nitrates/nitrites, phosphodiesterase 5 inhibitors and soluble guanylyl cyclase stimulators) have not provided symptomatic or exercise benefits in HFpEF. Mendelian randomization studies link IL-6 to the development of HFpEF; serum levels of IL-6 precede the development and track the severity of HFpEF; and experimental models point to IL-6 as a causal mediator of HFpEF. However, the adipokine hypothesis partitioned IL-6 and other classical cytokines from pathogenic adipokines in identifying molecular mediators of HFpEF, based on the observations that systemic IL-6 does not reliably reflect visceral adipose tissue dysfunction, and it is cosecreted with neutralizing cytokine antagonists. These observations suggested systemic IL-6 represents a distal marker, and not a mediator, of adipose tissue inflammation, and thus, unlikely to play a role in HFpEF. In proteomics analyses, heightened natural endogenous cytokine antagonists are more prominent and consistent features of HFpEF than circulating levels of the cytokines themselves. The HERMES trial tested the efficacy of the IL-6 antibody, ziltivekimab, in patients with HFpEF who were enriched for cytokine-mediated systemic inflammation, but the trial has been stopped for futility. Therefore, as a result of rigorous testing of each of its mechanistic layers, it is now difficult to support the hypothesis that HFpEF is a comorbidity-driven IL-6-mediated systemic inflammatory disorder that acts through or independently of a NO-cGMP deficiency mechanism.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America.","authors":"Eiran Z Gorodeski, Gregg C Fonarow, Parag Goyal, Faraz Shafique Ahmad, Nancy M Albert, Michelle Bloom, Biykem Bozkurt, Khadijah Breathett, Spencer J Carter, Richard K Cheng, Sarah Chuzi, Stephen A Clarkson, Jennifer Cowger, Ersilia M DeFilippis, Quin E Denfeld, Anita Deswal, Mark H Drazner, Shannon M Dunlay, Melvin R Echols, Marat Fudim, Olivia N Gilbert, Stephen J Greene, Justin L Grodin, Paul A Heidenreich, Scott L Hummel, Joshua A Jacobs, Manreet K Kanwar, Muhammad Shahzeb Khan, Michelle M Kittleson, Neal K Lakdawala, Christopher S Lee, Ahmad Masri, Robert Montgomery, Estefania Oliveros, Ambarish Pandey, Nosheen Reza, Alexander T Sandhu, Andrew J Sauer, Varun Sundaram, W H Wilson Tang, Amanda R Vest, Esther Vorovich, Boback Ziaeian","doi":"10.1016/j.cardfail.2026.07.009","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.07.009","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics and Trends in Reported Amyloidosis-related Mortality in the United States, 1999−2023","authors":"VIKASH JAISWAL MD,&nbsp;YUSRA MASHKOOR MBBS,&nbsp;KRITI KALRA MD,&nbsp;DANISHA KUMAR MBBS,&nbsp;FAKHAR LATIF MBBS,&nbsp;YUSRA MINAHIL NASIR MD,&nbsp;GREGG C. FONAROW MD,&nbsp;KEVIN M. ALEXANDER MD,&nbsp;ARMAN QAMAR MD","doi":"10.1016/j.cardfail.2025.10.006","DOIUrl":"10.1016/j.cardfail.2025.10.006","url":null,"abstract":"<div><h3>Background</h3><div>Amyloidosis represents a heterogeneous group of disorders characterized by extracellular deposition of misfolded protein fibrils, leading to progressive organ dysfunction and death. Despite its clinical significance, there is a paucity of large-scale epidemiologic data characterizing mortality trends associated with amyloidosis in the United States. We sought to evaluate temporal trends and demographic patterns in amyloidosis-related mortality across the US population from 1999 to 2023.</div></div><div><h3>Methods</h3><div>This population-based, retrospective cohort study used publicly available mortality data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database spanning from 1999 to 2023. The study included individuals of all ages in whom amyloidosis was listed as either an underlying or contributing cause of death on death certificates. The primary outcome was the age-adjusted mortality rate for amyloidosis-related deaths per 100,000 population. Age-adjusted mortality rates (AAMRs) were stratified by sex, race and ethnicity, US census region, state, place of death, and age group. Annual percentage changes (APCs) and 95% confidence intervals (CIs) were calculated to assess temporal trends.</div></div><div><h3>Results</h3><div>From 1999 to 2023, a total of 52,659 amyloidosis-related deaths were recorded in the United States. Most deaths occurred in medical facilities and homes. The overall AAMR nearly doubled from 4.95 (95% CI 4.68−5.21) in 1999 to 10.30 (95% CI 9.99−10.60) in 2022. After an initial period of relative stability from 1999 to 2012, AAMRs significantly increased from 2012 to 2018 (APC 5.24; 95% CI 3.87−10.36) and again from 2018 to 2023 (APC 11.13; 95% CI −48.67 to 17.07). Male patients consistently exhibited greater mortality rates than female patients (8.24 vs 4.20), and among racial/ethnic groups, non-Hispanic Black individuals had the greatest AAMR (11.26), whereas non-Hispanic Asians had the lowest (3.46). Since 2014, all US census regions have shown a significant increase in amyloidosis-related AAMRs, after earlier periods of stability or modest increases. States such as Massachusetts, Vermont, Minnesota, and the District of Columbia exhibited the greatest mortality burdens, whereas states like Louisiana, Arkansas, and Mississippi had the lowest. Mortality rates increased with advancing age, with individuals aged ≥85 years exhibiting the greatest crude mortality rate (64.29).</div></div><div><h3>Conclusions</h3><div>Amyloidosis-related mortality has markedly increased over the past 2 decades in the United States, with significant disparities across sex, age, racial/ethnic, and geographic groups. These increasing mortality rates likely reflect heightened diagnostic recognition rather than therapeutic failure, underscoring the need for earlier diagnosis, equitable access to care, and targeted screening of high-risk populations.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 10","pages":"Pages 1767-1777"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145488540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure","authors":"MANDEEP R. MEHRA MD, MSc,&nbsp;ADITI NAYAK MD,&nbsp;GIANLUIGI SAVARESE MD, PhD,&nbsp;MANREET K. KANWAR MD,&nbsp;SHELLEY HALL MD,&nbsp;KOICHIRO KINUGAWA MD,&nbsp;MILICA VUKICEVIC MD,&nbsp;MAJA CIKES MD, PhD,&nbsp;AKSHAY S. DESAI MD, MPH,&nbsp;EZEQUIEL J. MOLINA MD,&nbsp;MICHAEL M. GIVERTZ MD,&nbsp;MARIA G. CRESPO-LEIRO MD,&nbsp;DANIEL J. GOLDSTEIN MD,&nbsp;ROBERT L. KORMOS MD","doi":"10.1016/j.cardfail.2026.07.010","DOIUrl":"10.1016/j.cardfail.2026.07.010","url":null,"abstract":"&lt;div&gt;&lt;div&gt;The management of advanced heart failure has been transformed by 2 parallel developments that have not yet been fully translated into clinical practice. Heart transplantation and durable left ventricular assist device (LVAD) support confer contemporary 1-year survival approaching 90%; yet, these therapies frequently are deployed only after the onset of progressive right ventricular dysfunction, cardiorenal injury, severe frailty, and hemodynamic instability, which are conditions that elevate procedural risk, impair long-term outcomes, and may ultimately preclude candidacy for advanced therapies altogether. The central limitation in advanced heart failure is therefore no longer the absence of effective therapies but the failure to identify and refer patients during the therapeutic window when physiologic reserve remains intact. This special communication advances 2 related but distinct objectives. First, we propose PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer), a pragmatic referral framework in which the presence of any 2 of 4 early signals including escalating Loop diuretic requirements, recurrent Admissions, Therapy intolerance, and Early electrical, echocardiographic, or end-organ deterioration supplemented by persistently elevated natriuretic peptides—should prompt consideration for referral through shared care to an advanced heart failure program. These LATE criteria are designed to identify patients earlier in the disease trajectory than existing frameworks, when the full breadth of advanced therapy options is still intact. We further propose a multidisciplinary in-reach model, embedding advanced heart failure expertise within high-risk cardiovascular programs, including electrophysiology, structural heart, cardiogenic shock, cardiac surgery, and specialized cardiomyopathy services, to proactively identify and intercept residual risk before conventional referral triggers emerge. Second, and equally important, this communication provides a consolidated framework for contemporary LVAD best practices, an area in which clinical evidence has advanced rapidly but awareness and adoption remain inconsistent. We synthesize current evidence on morbidity decompression, pharmacologic optimization including renin-angiotensin-aldosterone system inhibition, myocardial recovery, frailty reversibility, and therapeutic sequencing including LVAD-first strategies, with the explicit goal of equipping clinicians to deploy these therapies earlier and more confidently. Critically, PREVENT 2-LATE is not designed to increase use of any single modality. Both heart transplantation and LVAD support are effective, and the framework exists precisely to preserve optionality across the full spectrum of advanced heart failure therapies, enabling expert multidisciplinary teams to match the right intervention to the right patient at the right time. The future of advanced heart failure lies not in increasingly urgent rescue after irreversible dec","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 10","pages":"Pages 1781-1794"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Atrial Fibrillation on Hemodynamics, Oxygen Consumption, and Its Fick Determinants in Patients With Heart Failure With Preserved Ejection Fraction","authors":"STEPHEN J. FOULKES PhD,&nbsp;SARA MOURA-FERREIRA MD,&nbsp;MAURICIO MILANI MD, PhD,&nbsp;YOURI BEKHUIS MD,&nbsp;MAARTEN FALTER MD,&nbsp;BORIS DELPIRE MD,&nbsp;RIK PAUWELS MD,&nbsp;SARAH STROOBANTS MD,&nbsp;SIDDHARTH JOGANI MD,&nbsp;SIMON VANHENTENRIJK MD, PharmD, MSc,&nbsp;SIBEL ALTINTAS MD,&nbsp;RUTA JASAITYTE MD, PhD,&nbsp;JAN STASSEN MD, PhD,&nbsp;LIEVEN HERBOTS MD, PhD,&nbsp;GUIDO CLAESSEN MD, PhD,&nbsp;MARK J. HAYKOWSKY PhD,&nbsp;JAN VERWERFT MD, PhD","doi":"10.1016/j.cardfail.2025.12.007","DOIUrl":"10.1016/j.cardfail.2025.12.007","url":null,"abstract":"<div><h3>Objective</h3><div>Atrial fibrillation (AF) is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF) that contributes to increased morbidity and mortality. We sought to evaluate the impact of AF on key HFpEF features, including exercise tolerance (peak oxygen uptake, VO₂peak) hemodynamic responses, and peripheral oxygen extraction (a-vO₂diff).</div></div><div><h3>Methods</h3><div>Patients referred to a multidsciplinary clinic for evaluation of unexplained dyspnea and diagnosed with HFpEF after a comprehensive clinical and hemodynamic evaluation were stratified on the basis of whether they were in persistent/permanent AF (AF_Persist; n = 86), paroxysmal AF (AF_Parox; n = 328), or sinus rhythm (SR; n = 274). Cardiopulmonary exercise testing with simultaneous echocardiography was applied to assess the VO₂peak, a-vO₂diff, and exercise hemodynamics. Groups were compared using analysis of covariance with adjustment for age, sex, body mass index, and the presence of hypertension and diabetes.</div></div><div><h3>Results</h3><div>Compared with patients in SR or with AF_Parox, patients with HFpEF and AF_Persist had a lower VO₂peak (1.3−2.4 mL/kg/min lower, <em>P</em> &lt; .001). This coincided with lower peak exercise cardiac output (CO, 0.6−1.2 L/min lower), secondary to a lesser stroke volume (14−17 mL lower, <em>P</em> &lt; .001), and a smaller left ventricular end-diastolic volume (15−18 mL lower, <em>P</em> &lt; .001) that tended to decrease during exercise. In contrast, there was no impact of AF status on peak exercise a-vO₂diff, mean pulmonary artery pressure or the mean pulmonary artery pressure/CO slope.</div></div><div><h3>Conclusions</h3><div>Patients with HFpEF and AF_Persist have a lower VO₂peak secondary to decreased CO, SV, and reduced end-diastolic volume reserve. Rhythm control strategies may therefore be pivotal in optimizing exercise performance and clinical outcomes in patients with HFpEF and AF.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 10","pages":"Pages 1715-1726"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}